Joined Bio passes 10,000 new participants in first year

Joined Bio says more than 10,000 people joined its direct-to-patient research platform in the year after launch, as the company expanded AI tools, study matching and at-home sample collection. The milestone underscores growing demand for faster recruitment and specimen delivery across life sciences research.

Why it matters: - Joined Bio is trying to speed up medical research by connecting participants, health records and biospecimens in one platform. - The first-year results suggest researchers can recruit participants and receive samples faster than traditional study pipelines allow. - The company is also positioning itself for demand from health AI teams that need patient data, samples and digital biomarkers.

What happened: - Joined Bio said more than 10,000 new participants joined since its late-2025 platform launch. - The company shared the update on November 2, 2026, in Lexington, Massachusetts. - Joined Bio also said it rolled out multiple platform features and supported direct-to-patient studies in vaccine research, autoimmune research and healthy donors.

The details: - Joined Bio said 40% of participants with connected health records have already joined a study. - The company said participants have received tens of thousands of dollars for at-home biospecimen collections and surveys. - Joined Bio said it has maintained a 5-star rating in participant reviews on Google. - The company has supported more than 90 research projects for more than 30 clients. - First-year work included delivering blood, plasma, serum and swabs, along with participant surveys. - In one study, Joined Bio went from purchase order to samples in the researcher’s hands in six days. - For healthy donor studies, Joined Bio said fresh samples were delivered within hours of collection. - Joined Bio said the platform launched in October 2025, along with BioCircle, its participant community. - The company announced the acquisition of DNAsimple in November 2025. - Joined Bio launched a referral program in December 2025. - The company closed a venture investment in February 2026. - Joined Bio introduced Complete Health Record and Self-Reported Health Data in April 2026. - The company launched Nova, an AI assistant for participant questions and medical document uploads, in September 2026.

Between the lines: - The 40% participation rate suggests the platform’s matching and engagement tools are getting people to act, not just sign up. - Faster turnaround times can make Joined Bio more appealing to researchers who need samples on short timelines. - The company’s push into AI for health points to a broader market beyond traditional clinical research.

What's next: - Joined Bio plans to deepen AI-powered study matching in its second year. - The company wants to grow its participant community in additional disease areas. - Joined Bio also plans to expand support for organizations building AI for health. - The company said participants can join at Joined Bio signup. - More information is available at the company’s website.